Lerdelimumab

Lerdelimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TGF beta 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development discontinued
Identifiers
CAS Number
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results.[2]

References

  1. ↑ "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D. Adis International. 3 (2): 106–108. 1 February 2002. doi:10.2165/00126839-200203020-00006.
  2. ↑ "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.